Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over

Supporting evidence

• Evaluation report

• Final evaluation determination committee papers (PDF 1.47 MB)

  Published:

  05 May 2022

• Evaluation consultation committee papers (PDF 4.87 MB)

  Published:

  05 May 2022